Table 1.
Demographic and clinical characteristics of the study subjects*
| Patients with PsA | Patients with RA | ||||
|---|---|---|---|---|---|
| All PsA (n = 33) | Paired PB/SF (n = 21) | All RA (n = 24) | Paired PB/SF (n = 14) | Healthy controls (n = 14) | |
| Female, no. (%) | 12 (36) | 6 (29) | 18 (75) | 10 (71) | 8 (57) |
| Age, mean ± SEM years | 45.1 ± 2.86 | 43.8 ± 3.73 | 54.3 ± 2.54 | 53.5 ± 3.20 | 43.8 ± 3.03 |
| Oligoarthritis, no. (%) | 25 (76) | 16 (76) | 0 (0) | 0 (0) | – |
| Disease duration, mean ± SEM years | 8.7 ± 1.43 | 7.3± 1.57 | 9.2 ± 1.73 | 12.2 ± 2.45 | – |
| Treatment, no. (%) | |||||
| Biologics | 8 (24) | 6 (29) | 4 (17) | 1 (7) | – |
| DMARDs | 12 (36) | 8 (38) | 17 (71) | 10 (71) | – |
| No treatment | 13 (39) | 7 (33) | 3 (12) | 3 (21) | – |
| DAS28 | |||||
| Mean ± SEM | 3.99 ± 0.21 | 3.87 ± 0.24 | 4.05 ± 0.32 | 4.79 ± 0.36 | – |
| Range | 1.6–6.6 | 1.4–6.9 | |||
| ESR, mean ± SEM mm/hour | 24.4 ± 4.42 | 29.9 ± 6.07 | 22.8 ± 2.86 | 23.4 ± 4.22 | – |
| CRP, mean ± SEM gm/dl | 31.8 ± 8.43 | 42.2 ± 12.0 | 13.0 ± 2.53 | 17.2 ± 4.10 | – |
| Erosive disease, no. (%) | 19 (57) | 13 (62) | 19 (80) | 12 (85) | – |
*
In total, 33 patients with psoriatic arthritis (PsA), 24 patients with rheumatoid arthritis (RA), and 14 healthy control subjects were recruited into the study. None of the patients had pure spondyloarthritis, arthritis mutilans, or distal interphalangeal joint arthritis. PB = peripheral blood; SF = synovial fluid; DMARDs = disease-modifying antirheumatic drugs; DAS28 = Disease Activity Score in 28 joints; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.